Background Atopic dermatitis is a chronic pruritic inflammatory skin disease commonly occurring in children. The objective of this study is to evaluate the treatment of pediatric atopic dermatitis with biologics, as they have displayed immense promising results in several recent clinical trials on atopic dermatitis (AD). Methods We will conduct an extensive search for RCTs in several databases, including Embase, Cochrane Library, Web of Science, and PubMed, from the inception of the study till 15th May 2022. The primary outcomes will be the proportion of patients with EASI 75/90/100 after 12–16 weeks of treatment. The secondary outcomes will include the Numerical Rating Scale (NRS), Investigator Global Assessment (IGA)0–1, body surface area (BSA), Dermatology Life Quality Index (DLQI) scores, and incidence of adverse reactions. All studies will be screened by two independent researchers. They will assess the risk of bias in the included studies according to the RCTs bias risk evaluation tool in Cochrane System Review Manual 5.1.0. Meta-analysis will be performed using RevMan V.5.3.0 software. Results The research results will provide a reference for the clinical application of biological agents in pediatric atopic dermatitis. Conclusion We aim to evaluate the efficacy and safety of biologics in pediatric atopic dermatitis cases and provide evidence-based data for easy clinical application. PROSPERO registration number CRD42022319052 (https://www.crd.york.ac.uk/PROSPERO/#joinuppage).

Background:  Atopic dermatitis is a common chronic pruritic inflammatory skin disease, tends to occur in children. The objective of this study is to evaluate the treatment of pediatric atopic dermatitis with Biologics,as biologics continue to emerge for atopic dermatitis (AD) Methods: The databases we will search include Embase, Cochrane Library, Web of Science,the and PubMed of RCTs from inception to 15st May 2022. The primary outcomes The proportion of patients with EASI 75 as the primary outcome,. The secondary outcomes incloud NRS,DLQI score and adverse reaction incidence.Studies will be screened by two independent authors. They will assess the risk of bias of the final included studies according to the RCTs bias risk evaluation tool in Cochrane System Review Manual 5.1.0. Meta-analysis will be performed using RevMan 5.3 software. Results: The research results will provide a reference for the clinical application of biological agents in pediatric atopic dermatitis. Conclusion: We aims to evaluate the efficacy and safety of biologics in pediatric atopic dermatitis and provide evidence-based data for clinical application Ethics and dissemination? The study does not collect raw data and personal information, does not involve jeopardizing the rights of the participants. Ethical approval was not required. The results may be reported in publications and the media PROSPERO registration   number: CRD42022319052 (https://www.crd.york.ac.uk/PROSPERO/#joinuppage) Abbreviations: AD:atopic dermatitis; RCT:randomized controlled trial;.SMD:Standard Mean Difference; RR:risk ratio;CI:confidence interval;EASI:Eczema Area and Severity Index; DLQI: Dermatology Life Quality Index; NRS?Numerical Rating Scale.